market access - pharmagenesis.com · value, so that the right messages, supported by robust...
TRANSCRIPT
www.pharmagenesis.com
@OxPharmaGenesis
Oxford+44 1865 390144
London+44 203 675 7060
Philadelphia+1 215 497 9699
Cardiff+44 292 064 7000
Basel+41 61 204 4561
HEALTHSCIENCE
The new discipline of clinical, economic,
social, behavioural and political
understanding that is essential for
demonstrating value in the healthcare
systems of today and tomorrow
Applying HealthScience thinking to optimize
patient access
Governments, payers, prescribers and patients are increasingly demanding evidence of the value of new healthcare products – they want to pay for outcomes, not just pills and procedures. At Oxford PharmaGenesis we understand that successful patient access requires an integrated approach to demonstrating brand value, so that the right messages, supported by robust evidence, are communicated to local, national and international decision-makers at the right time.
Our Value Demonstration Practice has a proven track record in delivering decision-shaping real-world evidence and value communications programmes for early-phase to mature products across all therapeutic areas, and non-pharmaceutical healthcare products. We achieve this through our unique understanding of HealthScience – the new discipline of clinical, economic, social, behavioural and political understanding that is essential for demonstrating value to all stakeholders who influence access to health care. Contact us today to find out about going beyond market access to patient access.
Richard White MA PhD
Commercial Director
Beyond
market access Medical communications Health policy
$ Patient engagement
Value demonstration
Commercialization Rare and orphan diseases
Publications Real-world evidence
www.pharmagenesis.com
@OxPharmaGenesis
Oxford+44 1865 390144
London+44 203 675 7060
Philadelphia+1 215 497 9699
Cardiff+44 292 064 7000
Basel+41 61 204 4561
HEALTHSCIENCE
The new discipline of clinical, economic,
social, behavioural and political
understanding that is essential for
demonstrating value in the healthcare
systems of today and tomorrow
Applying HealthScience thinking to optimize
patient access
Governments, payers, prescribers and patients are increasingly demanding evidence of the value of new healthcare products – they want to pay for outcomes, not just pills and procedures. At Oxford PharmaGenesis we understand that successful patient access requires an integrated approach to demonstrating brand value, so that the right messages, supported by robust evidence, are communicated to local, national and international decision-makers at the right time.
Our Value Demonstration Practice has a proven track record in delivering decision-shaping real-world evidence and value communications programmes for early-phase to mature products across all therapeutic areas, and non-pharmaceutical healthcare products. We achieve this through our unique understanding of HealthScience – the new discipline of clinical, economic, social, behavioural and political understanding that is essential for demonstrating value to all stakeholders who influence access to health care. Contact us today to find out about going beyond market access to patient access.
Richard White MA PhD
Commercial Director
Beyond
market access Medical communications Health policy
$ Patient engagement
Value demonstration
Commercialization Rare and orphan diseases
Publications Real-world evidence
www.pharmagenesis.com
@OxPharmaGenesis
Oxford+44 1865 390144
London+44 203 675 7060
Philadelphia+1 215 497 9699
Cardiff+44 292 064 7000
Basel+41 61 204 4561
HEALTHSCIENCE
The new discipline of clinical, economic,
social, behavioural and political
understanding that is essential for
demonstrating value in the healthcare
systems of today and tomorrow
Applying HealthScience thinking to optimize
patient access
Governments, payers, prescribers and patients are increasingly demanding evidence of the value of new healthcare products – they want to pay for outcomes, not just pills and procedures. At Oxford PharmaGenesis we understand that successful patient access requires an integrated approach to demonstrating brand value, so that the right messages, supported by robust evidence, are communicated to local, national and international decision-makers at the right time.
Our Value Demonstration Practice has a proven track record in delivering decision-shaping real-world evidence and value communications programmes for early-phase to mature products across all therapeutic areas, and non-pharmaceutical healthcare products. We achieve this through our unique understanding of HealthScience – the new discipline of clinical, economic, social, behavioural and political understanding that is essential for demonstrating value to all stakeholders who influence access to health care. Contact us today to find out about going beyond market access to patient access.
Richard White MA PhD
Commercial Director
Beyond
market access Medical communications Health policy
$ Patient engagement
Value demonstration
Commercialization Rare and orphan diseases
Publications Real-world evidence
Value communications for all of your key stakeholdersEffective communication and training is essential for optimizing cross-functional
collaboration with the full range of influencers and decision-makers – not only
clinicians and payers, but increasingly patients, advocacy groups and politicians.
We ensure that all key stakeholders are in a position to endorse patient
access, through:
• multidisciplinary internal and external workshops and expert panels
• internal HE&OR and market access communications and e-learning tools
• HE&OR publications and communications plans
• advocacy and consensus development
• disease area educational materials.
Early-phase product and disease area insightsEarly insights into high-value positioning options and patient segments are
essential for maximizing the revenue of a promising pipeline and ensuring
resonance with payers across markets. In providing strategic direction for
RWE analytics, as well as insight into stakeholder views on disease outcomes
and management, we support pipeline development and market access with:
• payer/stakeholder research and disease area mapping
• early value proposition development
• patient-reported outcome endpoint assessment
• reimbursement and competitive landscape evaluation.
Preparing a therapy area through RWE programmesEstablishing a real-world evidence (RWE) platform
is now a key part of product development and a
determinant of successful patient access. At Oxford
PharmaGenesis, our Systematic Understanding of
Real-world Evidence (SURE™) assessments use a
targeted, systematic and comprehensive approach
to identify the observational data sources that our
clients need to:
• inform patient selection criteria, and clinical
and economic endpoints for trials
• develop patient registries
• support product positioning that maximizes
market access
• assess long-term clinical benefits and rare
adverse events
• demonstrate real-world value through
comparative effectiveness.
Health technology assessmentHealth technology assessment (HTA) is increasingly
influencing patient access. Early planning provides
the foundation for a successful submission. We
support our clients in preparing for reimbursement
submissions and negotiations by providing:
• core value dossiers and implementation tools
• HTA submissions
• HTA-compliant systematic literature reviews
• expert panels and advisory boards
• budget impact modelling.
The Oxford PharmaGenesis approach
Therapy area insight analysis
Epidemiology Diseasedefinition
Guidelines Humanistic burden of
disease
Currenttreatment
patterns
Economic burden of
disease
Reimbursementlandscape
Budget-impactevidence
Cost-effectivenessevidence
Patient-reported outcome evidence
Clinicalevidence
Unmet medicalneed evidence
Politicians and patient advocacy
groups
Key opinion leadersand physicians
PayersPatientsRegulators
Patient and politicalacceptance
Guidelinesinclusion
Formulary uptakeand reimbursement
Education andawareness
Approval (efficacy,safety, quality)
Financialimpact
Value formoney
Patientbenefit
Therapeuticvalue
Medicalimportance
Value proposition development plan
Therapy area preparation programme Brand clinical development and HE&OR plans
Value communication plan – development and implementation
Compelling value proposition
Go beyond market access to patient access
Powerful thinking, dedicated to your success
www.pharmagenesis.com
@OxPharmaGenesis
Oxford+44 1865 390144
London+44 203 675 7060
Philadelphia+1 215 497 9699
Cardiff+44 292 064 7000
Basel+41 61 204 4561
HEALTHSCIENCE
The new discipline of clinical, economic,
social, behavioural and political
understanding that is essential for
demonstrating value in the healthcare
systems of today and tomorrow
Applying HealthScience thinking to optimize
patient access
Governments, payers, prescribers and patients are increasingly demanding evidence of the value of new healthcare products – they want to pay for outcomes, not just pills and procedures. At Oxford PharmaGenesis we understand that successful patient access requires an integrated approach to demonstrating brand value, so that the right messages, supported by robust evidence, are communicated to local, national and international decision-makers at the right time.
Our Value Demonstration Practice has a proven track record in delivering decision-shaping real-world evidence and value communications programmes for early-phase to mature products across all therapeutic areas, and non-pharmaceutical healthcare products. We achieve this through our unique understanding of HealthScience – the new discipline of clinical, economic, social, behavioural and political understanding that is essential for demonstrating value to all stakeholders who influence access to health care. Contact us today to find out about going beyond market access to patient access.
Richard White MA PhD
Commercial Director
Beyond
market access Medical communications Health policy
$ Patient engagement
Value demonstration
Commercialization Rare and orphan diseases
Publications Real-world evidence